Second, we showed that inhibition of TGF‐β1 using a neutralizing antibody markedly reduced endogenous HOXD9 levels and TGF‐β‐triggered HOXD9 expression in CRC (Figure 5C). The gene discussed is TGFB1; the disease is colorectal carcinoma.